IMPROVE-IT

Discussion in 'Merck' started by Anonymous, Nov 8, 2014 at 9:29 AM.

Tags: Add Tags
  1. Anonymous

    Anonymous Guest

    If you think IMPROVE-IT hit its endpoint, you are delusional.
     

  2. Anonymous

    Anonymous Guest

    Crestor still the best.
     
  3. Anonymous

    Anonymous Guest

    Yes , just like I told you last week. It is all about the reduction in ldl. Ezetimibe added on to a statin gives an imcremental benefit. " The results today are positive for Merck’s Zetia and Vytorin but go beyond by suggesting that LDL lowering with drugs other than statins provides a cardiovascular benefit (a reaffirming of the LDL hypothesis that was beginning to be questioned) and that LDL levels should possibly be driven lower than guidelines have recommended (below 70 mg/dl). Today’s results add the first real data point to our understanding of the relationship between LDL reduction and outcomes at very low LDL levels…"
     
  4. Anonymous

    Anonymous Guest